Rotavirus infection primary prevention: Difference between revisions
Gerald Chi- (talk | contribs) mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Rotavirus infection}} | {{Rotavirus infection}} | ||
{{CMG}} | {{CMG}}{{AE}}{{AEL}} | ||
== Vaccines == | ==Overview== | ||
==Primary prevention== | |||
===Vaccines=== | |||
In 2006, two vaccines against Rotavirus infection were shown to be safe and effective in children: Rotarix by [[GlaxoSmithKline]] and RotaTeq by [[Merck & Co., Inc.|Merck]]. Both are taken orally and contain disabled live virus. In February 2006, the [[U.S. Food and Drug Administration]] approved RotaTeq for use in the United States. Merck announced a price of $187.50 for the standard three-dose regimen; this is much more expensive than other standard childhood immunizations and, even allowing for discounts, will probably prevent widespread use of the vaccine in poor countries. However, Merck is selling vaccines at dramatically lower prices in developing world countries and is working with a range of partners including the Rotavirus Vaccine Project, PATH and other governmental and non-governmental organizations to develop and implement mechanisms for providing access to this vaccine in the developing world. | In 2006, two vaccines against Rotavirus infection were shown to be safe and effective in children: Rotarix by [[GlaxoSmithKline]] and RotaTeq by [[Merck & Co., Inc.|Merck]]. Both are taken orally and contain disabled live virus. In February 2006, the [[U.S. Food and Drug Administration]] approved RotaTeq for use in the United States. Merck announced a price of $187.50 for the standard three-dose regimen; this is much more expensive than other standard childhood immunizations and, even allowing for discounts, will probably prevent widespread use of the vaccine in poor countries. However, Merck is selling vaccines at dramatically lower prices in developing world countries and is working with a range of partners including the Rotavirus Vaccine Project, PATH and other governmental and non-governmental organizations to develop and implement mechanisms for providing access to this vaccine in the developing world. | ||
Revision as of 19:19, 28 April 2017
|
Rotavirus infection Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rotavirus infection primary prevention On the Web |
|
American Roentgen Ray Society Images of Rotavirus infection primary prevention |
|
Risk calculators and risk factors for Rotavirus infection primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Primary prevention
Vaccines
In 2006, two vaccines against Rotavirus infection were shown to be safe and effective in children: Rotarix by GlaxoSmithKline and RotaTeq by Merck. Both are taken orally and contain disabled live virus. In February 2006, the U.S. Food and Drug Administration approved RotaTeq for use in the United States. Merck announced a price of $187.50 for the standard three-dose regimen; this is much more expensive than other standard childhood immunizations and, even allowing for discounts, will probably prevent widespread use of the vaccine in poor countries. However, Merck is selling vaccines at dramatically lower prices in developing world countries and is working with a range of partners including the Rotavirus Vaccine Project, PATH and other governmental and non-governmental organizations to develop and implement mechanisms for providing access to this vaccine in the developing world.
An earlier vaccine, Rotashield by Wyeth-Ayerst, had to be taken off the market in the late 1990s after it was discovered in rare cases to be linked to a severe complication called intussusception. This event was so rare that widespread adoption of Rotashield in developing countries would nevertheless have saved millions of lives, but use of a vaccine deemed unsafe in the U.S. was seen as unacceptable.